复方血栓通胶囊辅治缺血性脑卒中的疗效及其对神经功能和血清 PARK7、GFAP 的影响

摘要

Objective To observe the effect of compound Xueshuantong capsule on ischemic stroke and neurological function and serum level of recombinant human Parkinson's disease protein 7 (PARK7) and glial fiber acidic protein (GFAP) level.Methods Selected 120 cases of patients with ischemic stroke diagnosed by CT from June 2013 to June 2015 at depart-ment of neurology, Shiyan People's Hospital Affiliated Hubei Medical College, according to the random number table method, they were divided into observation group and control group, 60 cases in each group,on basis of routine treatment,control group was given aspirin 100 mg orally, once a day;observation group based on the therapy of control group, also given compound Xueshuantong capsule 1.5 g, 3 times a day and continued treatment for 4 weeks.The effects of 2 groups were compared and analyzed, the changes of serum PARK7 and GFAP levels before and after treatment were compared.Results The observation group’s total effective rate was 96.67%, which was higher than that of the control group (83.33%, P <0.05).After treat-ment, in the observation group, the FMA score, Barthel Index and SIS score (50.4 ±12.6, 62.1 ±9.1, 71.2 ±7.6 respec-tively) were significantly higher than that of the control group (38.1 ±9.0, 53.2 ±9.3, 62.1 ±5.8;t =8.742、7.651、10.502, P <0.05), and the scores of NIHSS (11.9 ±4.0) was significantly lower than that of the control group (15.0 ± 4.4, t =5.926, P <0.05), and PARK7 (14.3 ±2.2) μg/L, GFAP (4.9 ±1.3) ng/ml level were lower than that of the control group (25.3 ±4.6) μg/L, (8.4 ±2.5) ng/ml ( t =13.888,9.665, P <0.05).Conclusion It demonstrated that the compound Xueshuantong capsule for treatment of ischemic stroke ccould effectively improve the neurological function, re-duce the level of serum GFAP and PARK7, which is beneficial to the prognosis of patients.%目的：观察复方血栓通胶囊辅治缺血性脑卒中的疗效及其对患者神经功能和血清重组人帕金森病蛋白7（PARK7）、神经胶质纤维酸性蛋白（GFAP）水平影响。方法选取2013年6月—2015年6月湖北医药学院附属十堰市人民医院神经内科经CT确诊为缺血性脑卒中的患者120例，按照随机数字表法分为观察组及对照组各60例，对照组在常规治疗的基础上给予阿司匹林100 mg口服，每天1次；观察组在对照组基础上给予复方血栓通1谮．5 g，每天3次，持续治疗4周。对比分析2组治疗效果及治疗前后血清PARK7、GFAP水平变化。结果观察组组总有效率为96．67％高于对照组83．33％（ P ＜0．05）。观察组治疗后FMA评分、Barthel指数及SIS评分分别为（50．4±12．6）分、（62．1±9．1）分、（71．2±7．6）分，均显著高于对照组的（38．1±9．0）分、（53．2±9．3）分、（62．1±5．8）分（t ＝8．742、7．651、10．502， P ＜0．05），而NIHSS评分（11．9±4．0）分显著低于对照组（15．0±4．4）分（ t ＝5．926， P ＜0．05）。观察组PARK7（14．3±2．2）μg／L、GFAP（4．9±1．3）ngm／l 水平均显著低于对照组（25．3±4．6）μg／L、（8．4±2．5）ng／ml（ t ＝13．888、9．665， P ＜0．05）。结论复方血栓通胶囊辅治缺血性脑卒中能有效改善患者神经功能，降低患者血清PARK7、GFAP水平，有利于患者预后。